By Fineline Cube Bio-Thera Solutions, Ltd. (SHA: 688177) announced that China’s National Medical Products Administration (NMPA) has approved its investigational new drug (IND) application to initiate a clinical study evaluating the combination of BAT3306, a biosimilar of Merck’s Keytruda (pembrolizumab), and BAT8008, the company’s proprietary Trop2-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Drug Profiles & Rationale for Combination
| Asset | Mechanism & Differentiation |
|---|---|
| BAT3306 | PD-1 monoclonal antibody biosimilar to Keytruda; designed to replicate efficacy and safety of the reference product at lower cost |
| BAT8008 | Trop2-directed ADC featuring: • Potent cytotoxic payload • Strong bystander effect (kills neighboring antigen-negative tumor cells) • High plasma stability and extremely low payload detachment rate • Favorable non-clinical safety profile |
The combination leverages immune checkpoint inhibition (BAT3306) to enhance T-cell activity alongside targeted tumor cell killing (BAT8008), with the bystander effect potentially overcoming heterogeneous Trop2 expression—a common challenge in solid tumors.
Clinical & Strategic Significance
- Cost-Efficient Innovation: By pairing an in-house Keytruda biosimilar with a novel ADC, Bio-Thera aims to deliver a high-value combo regimen without reliance on external partners or premium-priced originator drugs.
- Trop2 as High-Priority Target: Trop2 is overexpressed in multiple carcinomas (e.g., NSCLC, triple-negative breast cancer, urothelial), making BAT8008 a versatile backbone for combination strategies.
- China-First Development: The trial reinforces Bio-Thera’s dual focus on global biosimilars and innovative biologics, positioning it as a hybrid biopharma player in China’s evolving oncology landscape.
Competitive Context
- ADC Race Heats Up: Over 20 Trop2 ADCs are in clinical development globally; BAT8008’s low detachment rate and bystander potency may differentiate it from competitors like Daiichi Sankyo’s datopotamab deruxtecan.
- Biosimilar Leverage: Unlike innovators paying royalties for combo trials with Keytruda, Bio-Thera controls both assets—accelerating development and improving margin potential.
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, mechanism of action, and competitive positioning. Actual results depend on trial outcomes, regulatory decisions, and market dynamics.-Fineline Info & Tech